Our research focuses on gaining a better understanding of the inhibitory mechanisms, including inhibitory receptors and regulatory T cells, that limit anti-tumor immunity in cancer and are insufficient in autoimmune disease.
We also have make heavy use of system immunology approaches, discovery-based efforts and development of novel antibody-based therapeutics aimed at identifying novel targets and pathways for therapeutic intervention.
We are also working with UPMC Hillman Cancer Center scientists and clinicians to facilitate the translation of novel therapeutic modalities with a focus on immunologically impacted solid tumors (primarily melanoma and head & neck).